SCHEMBL6030294

SCHEMBL6030294

CCCCCCCCNC(=O)Nc1sc(C(=O)NCc2cccnc2)c(C)c1C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT4 P35916 2/20 0.52
FES P07332 1/20 0.52
RET P07949 1/20 0.52
MARK3 P27448 1/20 0.52
TYK2 P29597 1/20 0.52
SYK P43405 1/20 0.52
CLK2 P49760 1/20 0.52
CLK4 Q9HAZ1 1/20 0.52
TRPV1 Q8NER1 1/20 0.48
POLB P06746 3/20 0.47
RAB9A P51151 1/20 0.47
ALDH1A1 P00352 1/20 0.47
SCD O00767 1/20 0.45
NAMPT P43490 1/20 0.44
FAAH O00519 3/20 0.44
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6030084 0.92 CHRM4 (0.45) FLT4FESRETMARK3TYK2
SCHEMBL6031388 0.90 EPHX1 (0.49) ALDH1A1SCDHPGD
SCHEMBL6030206 0.89 NAMPT (0.48) POLBALDH1A1NAMPTKDM4ESMN1; SMN2
SCHEMBL6029645 0.88 ALDH1A1 (0.49) FLT4FESRETMARK3TYK2
SCHEMBL6031389 0.84 ALDH1A1 (0.47) POLBRAB9AALDH1A1HSD17B10KDM4E
SCHEMBL6030452 0.83 KMT2A (0.49) POLBRAB9AALDH1A1CYP1A2CYP3A4
SCHEMBL6030066 0.83 EPHX1 (0.48) POLBRAB9AALDH1A1CYP1A2CYP3A4
SCHEMBL6030406 0.82 EPHX1 (0.46) ALDH1A1HPGDNPSR1
SCHEMBL6030772 0.82 EPHX1 (0.46) ALDH1A1HPGDNPSR1
SCHEMBL6030269 0.82 EPHX1 (0.46) ALDH1A1HPGDNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7064122-B2 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2006-06-20 US disclosed
EP-1467978-A4 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARM INC (US) 2005-11-02 EP disclosed
EP-1467978-A1 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI Pharmaceuticals, Inc. (US) 2004-10-20 EP disclosed
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. 2003-10-16 US disclosed
WO-2003053944-A1 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARMACEUTICALS, INC. (US) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use PNLIP, LIPC, CEL FLT4 3559/4885FES 4418/4885RET 713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.